| |
|
|
|
RepliCel CEO Provides Corporate Update
|
|
Vancouver, BC, February 10, 2021--RepliCel Life Sciences Inc. (TSXV: RP), a company developing next-generation technologies in aesthetics and orthopedics, has provided an update to shareholders from its Board and Management represented by President and CEO, Mr. R. Lee Buckler.
|
|
|
|
|
|
|
|
|
|
|
|
RepliCel Secures Several New Patents for its Regenerative Medicine Technologies
|
|
Vancouver, BC, April 26, 2019--RepliCel Life Sciences Inc. (TSXV: RP) (FRA:P6P2), a company developing next-generation technologies in aesthetics and orthopedics, announced that it has recently received notifications of several patents issued, allowed, and granted to the Company from Europe, China, Hong Kong, Japan, the United States and South Africa.
|
|
|
|
|
|
|
|
RepliCel Says Licensee YOFOTO (China) Health Building Momentum in China with Facility and Team
|
|
Vancouver, BC, March 26, 2019--RepliCel Life Sciences Inc. (TSXV: RP), a company developing next-generation technologies in aesthetics and orthopedics, announced that its Licensee, YOFOTO (China) Health Co., headquartered in Ningbo, China, is rapidly building momentum on its licensed programs for Greater China, since closing the transaction with RepliCel in October last year.
|
|
|
|
|
|
|
|
RepliCel Reignites its First-in-Japan Strategy
|
|
Vancouver, BC, March 22, 2019--RepliCel Life Sciences Inc. (TSXV: RP), a company developing next-generation technologies in aesthetics and orthopedics, has announced the resumption of their First-in-Japan strategy.
|
|
|
|
|
|
|
|
RepliCel CEO Provides 2019 Shareholder Update
|
|
Vancouver, BC, March 12, 2019--RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP), a company developing next-generation technologies in aesthetics and orthopedics, provided an update to shareholders this week from its President and CEO, Mr. R. Lee Buckler (see original text below).
|
|
|
|
|
|
|
|
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
|
|
Vancouver, BC, December 4, 2018--RepliCel Life Sciences Inc. (TSXV: RP) , a company developing next-generation technologies in aesthetics and orthopedics, has announced the appointment of European Clinical and Regulatory Affairs expert, Dr. Petra Goessens-Rueck, as Head of Clinical and Regulatory Affairs.
|
|
|
|
|
|
|
|
RepliCel Life Sciences Appoints New Chief Financial Officer
|
|
Vancouver, BC, October 30, 2018--RepliCel Life Sciences Inc. (TSXV: RP), a company developing next-generation technologies in aesthetics and orthopedics, announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company.
|
|
|
|
|
|
|
|
RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete $5M Investment
|
|
Vancouver, BC, October 5, 2018--RepliCel Life Sciences Inc. (TSXV: RP), a company developing next-generation technologies in aesthetics and orthopedics, announced this week that it has received, from the TSX Venture Exchange, the conditional approval required to complete the investment which is part of a previously announced collaboration agreement focused on commercialization of select RepliCel products in Greater China.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
